Wyeth, Santaris Ink RNA-Based Medicine-Development Deal

Biopharmaceutical companies Wyeth and Santaris Pharma announced a joint alliance to develop new RNA-based medicines, a deal under which Wyeth could make up to $100 million in cash and equity investments in Denmark-based Santaris.
CNN Money